Press release -
Cavidi closes US$ 11.5 million financing with Impilo
Cavidi AB is an Uppsala-based diagnostics company focused on HIV Viral Load monitoring. The company has developed a new fully automated viral load diagnostic platform. This platform, Ziva, aims to meet the need for cost-effective monitoring in high-disease burden countries.
“We launched development of the Ziva platform with a loan from the European Investment Bank, our first institutional capital.We have now largely completed Ziva development and established a distribution agreement with a top 10 global diagnostic company. With this financing, we have secured the growth equity to support Ziva’s launch. We are pleased to welcome Impilo as one of our major owners,” says John Reisky de Dubnic CEO at Cavidi.
“Impilo has a long-term approach to building value and aim to produce lasting positive effects in the health care sector. We believe that the success of the companies we invest in depends on their contribution to a positive development of society through improved products and services. Impilo is therefore a good fit for Cavidi”, says Fredrik Strömholm, Founder and Partner at Impilo. “Cavidi’s focus on delivering technology that enables healthcare systems to implement the WHO guidelines on how to better monitor HIV, we believe will provide tremendous value. Our objective is that our contribution will help Cavidi grow to become a strong diagnostics company with global impact on HIV/AIDS containment”, says Veronica Byfield Sköld, Partner at Impilo.
Impilo, an investment company focusing on Nordic healthcare companies and established in 2017, has more than SEK 3 bn in capital from leading Nordic and international investors.
For more information, contact:
John Reisky de Dubnic, CEO of Cavidi
Fredrik Strömholm, Partner, Impilo
Veronica Byfield Sköld, Partner, Impilo
veronica.skold@impilo.se
Related links
Topics
- Finance
Cavidi is Sweden’s leading supplier of viral load for HIV monitoring. Cavidi’s products enable efficient management of anti-HIV drugs (ARV therapy) so that people living with HIV can live a normal lifespan. Cavidi’s diagnostics reduce the cost of treatment and the spread of HIV. Cavidi also provides tools and kits for virus research to many of the world’s leading labs.
Cavidi is a Swedish biotech company founded as a spin-off from Uppsala University. Our expertise is based on understanding viruses and using this knowledge to create research tools and clinical diagnostics. Today our focus is on HIV but our methods and expertise can be applied to other viruses.
Cavidi’s head office is in Uppsala, Sweden and we have sales offices in South Africa, India and USA. Our customers include hospitals, patient clinics, private laboratories, the pharmaceutical industry and research institutions worldwide.
Cavidi is ISO13485 certified for quality management systems.
